Skip to main content
Erschienen in: Cancer and Metastasis Reviews 2/2015

01.06.2015

Relationship between gene mutation and lung cancer metastasis

verfasst von: Rafael Rosell, Niki Karachaliou

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Cancer is a genetic disease occurring through a multi-step process. Many important genes responsible for the genesis of various cancers have been discovered, their mutations precisely identified and the pathways through which they act characterized. One question that remains unanswered is whether the development of new, more specific therapeutic agents is the best way to minimize cancer morbidity and mortality in the long-term. Metastasis is the relentless pursuit of cancer to escape its primary site and colonize distant organs. Phenotypic changes during cancer progression reflect the sequential accumulation of genetic alterations, which endow cancer cells with the ability to undergo their own divergent evolution and create distinct metastatic species. In order to understand this process, it is crucial to identify genes whose alterations accumulate during cancer progression and correlate with metastatic phenotypes of cancer cells.
Literatur
4.
Zurück zum Zitat Vidal, S. J., Rodriguez-Bravo, V., Galsky, M., Cordon-Cardo, C., & Domingo-Domenech, J. (2014). Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene, 33(36), 4451–4463. doi:10.1038/onc.2013.411.PubMedCrossRef Vidal, S. J., Rodriguez-Bravo, V., Galsky, M., Cordon-Cardo, C., & Domingo-Domenech, J. (2014). Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene, 33(36), 4451–4463. doi:10.​1038/​onc.​2013.​411.PubMedCrossRef
6.
Zurück zum Zitat Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., et al. (2014). Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics, 46(3), 225–233. doi:10.1038/ng.2891.PubMedCrossRef Gerlinger, M., Horswell, S., Larkin, J., Rowan, A. J., Salm, M. P., Varela, I., et al. (2014). Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nature Genetics, 46(3), 225–233. doi:10.​1038/​ng.​2891.PubMedCrossRef
7.
Zurück zum Zitat Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine, 366(10), 883–892. doi:10.1056/NEJMoa1113205.PubMedCrossRef Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New England Journal of Medicine, 366(10), 883–892. doi:10.​1056/​NEJMoa1113205.PubMedCrossRef
8.
Zurück zum Zitat Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., et al. (2014). Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 346(6206), 256–259. doi:10.1126/science.1256930.PubMedCrossRef Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., et al. (2014). Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 346(6206), 256–259. doi:10.​1126/​science.​1256930.PubMedCrossRef
9.
Zurück zum Zitat Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., et al. (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26(21), 3552–3559.PubMedCrossRef Pignon, J. P., Tribodet, H., Scagliotti, G. V., Douillard, J. Y., Shepherd, F. A., Stephens, R. J., et al. (2008). Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. Journal of Clinical Oncology, 26(21), 3552–3559.PubMedCrossRef
10.
Zurück zum Zitat Arriagada, R., Auperin, A., Burdett, S., Higgins, J. P., Johnson, D. H., Le Chevalier, T., et al. (2010). Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet, 375(9722), 1267–1277.PubMedCrossRef Arriagada, R., Auperin, A., Burdett, S., Higgins, J. P., Johnson, D. H., Le Chevalier, T., et al. (2010). Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet, 375(9722), 1267–1277.PubMedCrossRef
11.
Zurück zum Zitat Arriagada, R., Auperin, A., Burdett, S., Johnson, D., Le Chevalier, T., Le Pechoux, C., et al. (2014). Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet, 383(9928), 1561–1571.CrossRef Arriagada, R., Auperin, A., Burdett, S., Johnson, D., Le Chevalier, T., Le Pechoux, C., et al. (2014). Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet, 383(9928), 1561–1571.CrossRef
13.
Zurück zum Zitat Kratz, J. R., He, J., Van Den Eeden, S. K., Zhu, Z. H., Gao, W., Pham, P. T., et al. (2012). A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet, 379(9818), 823–832.PubMedCentralPubMedCrossRef Kratz, J. R., He, J., Van Den Eeden, S. K., Zhu, Z. H., Gao, W., Pham, P. T., et al. (2012). A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet, 379(9818), 823–832.PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Rosell, R., Taron, M., & Jablons, D. (2011). Lung cancer metastasis. In D. R. Welch, D. C. Lyden, & B. Psaila (Eds.), Cancer metastasis: Biologic basis and therapeutics (1st ed., pp. 369–381). New York: NY: Cambridge University Press. Cancer Metastasis.CrossRef Rosell, R., Taron, M., & Jablons, D. (2011). Lung cancer metastasis. In D. R. Welch, D. C. Lyden, & B. Psaila (Eds.), Cancer metastasis: Biologic basis and therapeutics (1st ed., pp. 369–381). New York: NY: Cambridge University Press. Cancer Metastasis.CrossRef
15.
Zurück zum Zitat Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., et al. (2012). KRAS and YAP1 converge to regulate EMT and tumor survival. Cell, 158(1), 171–184.CrossRef Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., et al. (2012). KRAS and YAP1 converge to regulate EMT and tumor survival. Cell, 158(1), 171–184.CrossRef
16.
Zurück zum Zitat Crawford, J., O’Rourke, M., Schiller, J. H., Spiridonidis, C. H., Yanovich, S., Ozer, H., et al. (1996). Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 14(10), 2774–2784.PubMed Crawford, J., O’Rourke, M., Schiller, J. H., Spiridonidis, C. H., Yanovich, S., Ozer, H., et al. (1996). Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. Journal of Clinical Oncology, 14(10), 2774–2784.PubMed
17.
Zurück zum Zitat Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine, 346(2), 92–98.PubMedCrossRef Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., et al. (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine, 346(2), 92–98.PubMedCrossRef
18.
Zurück zum Zitat Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., et al. (2000). Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. Journal of Clinical Oncology, 18(3), 623–631.PubMed Bonomi, P., Kim, K., Fairclough, D., Cella, D., Kugler, J., Rowinsky, E., et al. (2000). Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. Journal of Clinical Oncology, 18(3), 623–631.PubMed
19.
Zurück zum Zitat Hoang, T., Xu, R., Schiller, J. H., Bonomi, P., & Johnson, D. H. (2005). Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. Journal of Clinical Oncology, 23(1), 175–183.PubMedCrossRef Hoang, T., Xu, R., Schiller, J. H., Bonomi, P., & Johnson, D. H. (2005). Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. Journal of Clinical Oncology, 23(1), 175–183.PubMedCrossRef
20.
Zurück zum Zitat Postmus, P. E., Brambilla, E., Chansky, K., Crowley, J., Goldstraw, P., Patz, E. F., Jr., et al. (2007). The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. Journal of Thoracic Oncology, 2(8), 686–693.PubMedCrossRef Postmus, P. E., Brambilla, E., Chansky, K., Crowley, J., Goldstraw, P., Patz, E. F., Jr., et al. (2007). The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. Journal of Thoracic Oncology, 2(8), 686–693.PubMedCrossRef
21.
Zurück zum Zitat Reck, M., Heigener, D. F., Mok, T., Soria, J. C., & Rabe, K. F. (2013). Management of non-small-cell lung cancer: recent developments. Lancet, 382(9893), 709–719.PubMedCrossRef Reck, M., Heigener, D. F., Mok, T., Soria, J. C., & Rabe, K. F. (2013). Management of non-small-cell lung cancer: recent developments. Lancet, 382(9893), 709–719.PubMedCrossRef
22.
Zurück zum Zitat Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K. K. (2014). Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer, 14(8), 535–546. doi:10.1038/nrc3775.PubMedCrossRef Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F., & Wong, K. K. (2014). Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer, 14(8), 535–546. doi:10.​1038/​nrc3775.PubMedCrossRef
24.
Zurück zum Zitat Gazdar, A. F., & Minna, J. D. (2008). Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prevention Research (Philadelphia, Pa.), 1(3), 156–160. doi:10.1158/1940-6207.CAPR-08-0080.CrossRef Gazdar, A. F., & Minna, J. D. (2008). Deregulated EGFR signaling during lung cancer progression: mutations, amplicons, and autocrine loops. Cancer Prevention Research (Philadelphia, Pa.), 1(3), 156–160. doi:10.​1158/​1940-6207.​CAPR-08-0080.CrossRef
25.
27.
Zurück zum Zitat Kumar, M. S., Hancock, D. C., Molina-Arcas, M., Steckel, M., East, P., Diefenbacher, M., et al. (2012). The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell, 149(3), 642–655. doi:10.1016/j.cell.2012.02.059.PubMedCrossRef Kumar, M. S., Hancock, D. C., Molina-Arcas, M., Steckel, M., East, P., Diefenbacher, M., et al. (2012). The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell, 149(3), 642–655. doi:10.​1016/​j.​cell.​2012.​02.​059.PubMedCrossRef
28.
29.
Zurück zum Zitat Yoshimi, A., Goyama, S., Watanabe-Okochi, N., Yoshiki, Y., Nannya, Y., Nitta, E., et al. (2011). Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood, 117(13), 3617–3628. doi:10.1182/blood-2009-12-261602.PubMedCrossRef Yoshimi, A., Goyama, S., Watanabe-Okochi, N., Yoshiki, Y., Nannya, Y., Nitta, E., et al. (2011). Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood, 117(13), 3617–3628. doi:10.​1182/​blood-2009-12-261602.PubMedCrossRef
30.
Zurück zum Zitat Shih, M. C., Chen, J. Y., Wu, Y. C., Jan, Y. H., Yang, B. M., Lu, P. J., et al. (2012). TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene, 31(19), 2389–2400. doi:10.1038/onc.2011.419.PubMedCrossRef Shih, M. C., Chen, J. Y., Wu, Y. C., Jan, Y. H., Yang, B. M., Lu, P. J., et al. (2012). TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Oncogene, 31(19), 2389–2400. doi:10.​1038/​onc.​2011.​419.PubMedCrossRef
31.
Zurück zum Zitat Matsuo, Y., Park, J. H., Miyamoto, T., Yamamoto, S., Hisada, S., Alachkar, H., et al. (2014). TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Science Translational Medicine, 6(259), 259ra145. doi:10.1126/scitranslmed.3010277.PubMedCrossRef Matsuo, Y., Park, J. H., Miyamoto, T., Yamamoto, S., Hisada, S., Alachkar, H., et al. (2014). TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Science Translational Medicine, 6(259), 259ra145. doi:10.​1126/​scitranslmed.​3010277.PubMedCrossRef
33.
Zurück zum Zitat Yamadori, T., Ishii, Y., Homma, S., Morishima, Y., Kurishima, K., Itoh, K., et al. (2012). Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene, 31(45), 4768–4777. doi:10.1038/onc.2011.628.PubMedCrossRef Yamadori, T., Ishii, Y., Homma, S., Morishima, Y., Kurishima, K., Itoh, K., et al. (2012). Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene, 31(45), 4768–4777. doi:10.​1038/​onc.​2011.​628.PubMedCrossRef
35.
Zurück zum Zitat Schneeberger, V. E., Luetteke, N., Ren, Y., Berns, H., Chen, L., Foroutan, P., et al. (2014). SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis, 35(8), 1717–1725. doi:10.1093/carcin/bgu025.PubMedCrossRef Schneeberger, V. E., Luetteke, N., Ren, Y., Berns, H., Chen, L., Foroutan, P., et al. (2014). SHP2E76K mutant promotes lung tumorigenesis in transgenic mice. Carcinogenesis, 35(8), 1717–1725. doi:10.​1093/​carcin/​bgu025.PubMedCrossRef
36.
Zurück zum Zitat Uekita, T., Fujii, S., Miyazawa, Y., Iwakawa, R., Narisawa-Saito, M., Nakashima, K., et al. (2014). Oncogenic Ras/ERK Signaling Activates CDCP1 to Promote Tumor Invasion and Metastasis. Molecular Cancer Research, 12(10), 1449–1459. doi:10.1158/1541-7786.MCR-13-0587.PubMedCrossRef Uekita, T., Fujii, S., Miyazawa, Y., Iwakawa, R., Narisawa-Saito, M., Nakashima, K., et al. (2014). Oncogenic Ras/ERK Signaling Activates CDCP1 to Promote Tumor Invasion and Metastasis. Molecular Cancer Research, 12(10), 1449–1459. doi:10.​1158/​1541-7786.​MCR-13-0587.PubMedCrossRef
37.
Zurück zum Zitat Uekita, T., Jia, L., Narisawa-Saito, M., Yokota, J., Kiyono, T., & Sakai, R. (2007). CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Molecular Cell. Biology, 27(21), 7649–7660. doi:10.1128/MCB.01246-07.CrossRef Uekita, T., Jia, L., Narisawa-Saito, M., Yokota, J., Kiyono, T., & Sakai, R. (2007). CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Molecular Cell. Biology, 27(21), 7649–7660. doi:10.​1128/​MCB.​01246-07.CrossRef
38.
Zurück zum Zitat Frisch, S. M., & Screaton, R. A. (2001). Anoikis mechanisms. Current Opinion in Cell Biology, 13(5), 555–562.PubMedCrossRef Frisch, S. M., & Screaton, R. A. (2001). Anoikis mechanisms. Current Opinion in Cell Biology, 13(5), 555–562.PubMedCrossRef
39.
40.
Zurück zum Zitat Frisch, S. M., & Francis, H. (1994). Disruption of epithelial cell-matrix interactions induces apoptosis. Journal of Cell Biology, 124(4), 619–626.PubMedCrossRef Frisch, S. M., & Francis, H. (1994). Disruption of epithelial cell-matrix interactions induces apoptosis. Journal of Cell Biology, 124(4), 619–626.PubMedCrossRef
41.
Zurück zum Zitat Hisano, C., Tanaka, R., Fujishima, H., Ariyama, H., Tsuchiya, T., Tatsumoto, T., et al. (2003). Suppression of anoikis by v-Src but not by activated c-H-ras in human gallbladder epithelial cells. Cell Biology International, 27(5), 415–421.PubMedCrossRef Hisano, C., Tanaka, R., Fujishima, H., Ariyama, H., Tsuchiya, T., Tatsumoto, T., et al. (2003). Suppression of anoikis by v-Src but not by activated c-H-ras in human gallbladder epithelial cells. Cell Biology International, 27(5), 415–421.PubMedCrossRef
42.
Zurück zum Zitat Casar, B., Rimann, I., Kato, H., Shattil, S. J., Quigley, J. P., & Deryugina, E. I. (2014). In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene, 33(2), 255–268. doi:10.1038/onc.2012.547.PubMedCentralPubMedCrossRef Casar, B., Rimann, I., Kato, H., Shattil, S. J., Quigley, J. P., & Deryugina, E. I. (2014). In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene, 33(2), 255–268. doi:10.​1038/​onc.​2012.​547.PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Ikeda, J., Oda, T., Inoue, M., Uekita, T., Sakai, R., Okumura, M., et al. (2009). Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Science, 100(3), 429–433. doi:10.1111/j.1349-7006.2008.01066.x.PubMedCrossRef Ikeda, J., Oda, T., Inoue, M., Uekita, T., Sakai, R., Okumura, M., et al. (2009). Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Science, 100(3), 429–433. doi:10.​1111/​j.​1349-7006.​2008.​01066.​x.PubMedCrossRef
Metadaten
Titel
Relationship between gene mutation and lung cancer metastasis
verfasst von
Rafael Rosell
Niki Karachaliou
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 2/2015
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9557-1

Weitere Artikel der Ausgabe 2/2015

Cancer and Metastasis Reviews 2/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.